[Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer].
[Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer].
复制标题
DOI：
10.19540/j.cnki.cjcmm.20170523.005
复制
发表时间：
2017-07-01
期刊：
影响因子：
--
通讯作者：
Cheng, Miao
中科院分区：
文献类型：
--
作者：
He, Wei;Cheng, Miao
评价中药联合第一代表皮生长因子受体-TKI治疗晚期非小细胞肺癌（NSCLC）的疗效和安全性。计算机检索中国生物医学文献数据库（CBM）、中国期刊全文数据库（CNKI）、维普数据库（VIP）、PubMed、CochraneLibrary、EMbase等中英文数据库，查找中药联合第一代EGFR-TKI治疗晚期NSCLC的随机对照临床试验。统计学效果采用Revman 5.3.5基于总有效率、疾病控制率、生活质量、1年生存率、不良反应/事件等结局指标进行衡量。同时，通过Stata12.0进行偏倚风险评估。共纳入17个研究，涉及1 391例病例，其中治疗组706例，对照组685例。这些研究的特点是方法学质量低，同质性高，发表偏倚风险低。Meta分析结果显示，总有效率[RR=1.33，95%CI（1.17，1.51）]，疾病控制率[RR=1.21，95%CI（1.13，1.29）]、生活质量改善率[RR=1.28，95%CI（1.17，1.41）]，1年生存率[RR=1.27，95%CI（1.01，1.61）]，中药联合一代EGFR-TKI治疗的疗效及其他指标均上级单用一代EGFR-TKI，差异有显著性（P
To evaluate the efficacy and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer (NSCLC). China biomedical literature database (CBM), China Journal Full-text Database (CNKI), VIP, PubMed, CochraneLibrary, EMbase and other Chinese and English databases were searched for randomized and clinical controlled trials of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced NSCLC. The statistical effect was measured by Revman 5.3.5 based on the outcome indexes of total response rate, disease control rate, quality of life, one-year survival rate, and adverse reactions/events. Meanwhile, a bias risk assessment was conducted by Stata12.0. A total of 17 studies were included, involving 1 391 cases, with 706 cases in the treatment group and 685 cases in the control group. The studies featured a low methodological quality, high homogeneity and low publication bias risk. The meta-analysis showed that total response rate [RR=1.33, 95%CI (1.17, 1.51)], disease control rate [RR=1.21, 95%CI (1.13, 1.29)], quality of life improvement rate [RR=1.28, 95%CI (1.17, 1.41)], one-year survival rate [RR=1.27, 95%CI (1.01, 1.61)], and other indexes of effectiveness of Chinese medicine combined with first-generation EGFR-TKI were all superior to those of first-generation EGFR-TKI alone, with significant differences (P